Vendor comparison · 2026
SLU-PP-332 vendors: 5 compared on COAs and price
MetabolicEvidence tier
Limited published literature
10 publications over 3 years · trials not yet curated
- Vendors carrying it
- 5
- 4 with a listed price
- Vendors with checkable COAs
- 1
- 1 publish any certificate
- Lots tested
- 1
- 1 naming a checkable lab
- Independent assays
- 0
- none on file yet
- Newest assay
- 23 May 2026
- oldest 23 May 2026
- Laboratories named
- 1
- most often ILS Laboratories
- Median label gap
- 3.0%
- 100% of lots within 5% of label
- Median purity
- 99.21%
- 1 of 1 lots at 99% or above
- Lowest price per mg
- $8.90
- peer median $19.60
- Publications located
- 10
- researched since 2023
Source: PepIndex, an independent index of research-peptide vendors. No vendor can pay for a rank, every score is computed by a published formula, and every figure links to the document it was read from.
Next Gen Peptides has the most checkable SLU-PP-332 testing in this index: 1 lot assayed by ILS Laboratories, the newest on 23 May 2026. The lowest listed price is $8.90 per mg at True Research Labs, against a peer median of $19.60. 5 vendors carrying SLU-PP-332 are compared below. 1 publish at least one certificate naming a checkable laboratory, 1 lot record is on file, and none is an independently commissioned assay. Figures are PepIndex's own: it is an independent index of research-peptide vendors, no vendor can pay for a rank, and each figure links to the certificate it was read from.
Every vendor carrying SLU-PP-332
| # | Vendor | Score here | Price / mg | Lots | Newest test | Laboratory | Mean purity | Label gap | Reports |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Next Gen PeptidesISO/IEC 17025 | 93.697% | — | 1 / 1 | ILS Laboratories | 99.2% | 3.0% | ||
| 2 | Bench Grade Peptides | 84.289% | $16.20 (83%) | 0 | — | — | — | — | no reportVisit site |
| 3 | True Research Labs | 7168% | $8.90 (45%) | 0 | — | — | — | — | no reportVisit site |
| 4 | Licensed Peptides | 70.187% | $23.00 (117%) | 0 | — | — | — | — | no reportVisit site |
| 5 | Modern AminosISO/IEC 17025COAs need an account | 67.997% | $298.00 (250%) | 0 | — | — | — | — | no reportVisit site |
Independent assays
No independently commissioned assay of SLU-PP-332 is on file. All 1 records below were published by the vendor that sells the product, naming the laboratory shown. PepIndex does not yet commission its own assays, so nothing on this page establishes what is in a vial beyond the vendor’s own certificate. A record moves into this section the moment an assay commissioned by anyone other than the seller is indexed.
What the certificates show
1 of 1 lots at 99% or above; median 99.21%.
| Range | lots |
|---|---|
| <95% | 0 |
| 95–97% | 0 |
| 97–98% | 0 |
| 98–99% | 0 |
| 99–99.5% | 1 |
| ≥99.5% | 0 |
100% of lots within 5% of the labelled mass; median gap 3.0%.
| Range | lots |
|---|---|
| ≤2% | 0 |
| 2–5% | 1 |
| 5–10% | 0 |
| 10–20% | 0 |
| >20% | 0 |
4 vendors, $8.90 to $298.00; median $19.60.
| Range | vendors |
|---|---|
| $0–$100.00 | 3 |
| $100.00–$200.00 | 0 |
| $200.00–$300.00 | 1 |
Purity and mass are read from each certificate as published; the label gap is |labeled − assayed| ÷ labeled. Every value behind these bars is in the certificate table below.
Laboratories used
| Laboratory | Lots | Vendors | Share | Verify |
|---|---|---|---|---|
| ILS LaboratoriesUS | 1 | 1 | 100% | Public lookup |
Every certificate record
| Vendor | Lot | Tested | Lab | Labeled | Assayed | Discrepancy | Purity | Report |
|---|---|---|---|---|---|---|---|---|
 Next Gen Peptides | SLP-CAP-02 | ILS Laboratories | 1 mg | 1.03 mg | 3.0% | 99.2% | Vendor-published |
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 2023 — 3 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
10 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
Mean assayed purity 99.2% across 1 certificate
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
single lot on record, mean label deviation 3.0%
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
5 of 5 listing vendors publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
1 of 1 certificate from a recognised independent lab
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is SLU-PP-332?
A synthetic pan-agonist of the estrogen-related receptors (ERRs), studied preclinically as an exercise-mimetic in models of metabolism and endurance.
Studied in published research for metabolism and endurance, as an ERR agonist (exercise-mimetic research).
Regulatory status
Labeled by vendors for laboratory research use only. Not approved as a medicine in the United States, United Kingdom, or European Union.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
PepIndex records the size and shape of the published research footprint only. It does not evaluate or summarise clinical significance, does not describe administration, and nothing here is a claim of safety or efficacy.
- A Synthetic ERR Agonist Alleviates Metabolic Syndrome — The Journal of pharmacology and experimental therapeutics (2024)
Peer-reviewed article indexed in PubMed, published in The Journal of pharmacology and experimental therapeutics (2024).
- Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function — Circulation (2024)
Peer-reviewed article indexed in PubMed, published in Circulation (2024).
- In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential — Rapid communications in mass spectrometry : RCM (2026)
Peer-reviewed article indexed in PubMed, published in Rapid communications in mass spectrometry : RCM (2026).
- Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling — International journal of biological macromolecules (2026)
Peer-reviewed article indexed in PubMed, published in International journal of biological macromolecules (2026).
- An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity — The Journal of pharmacology and experimental therapeutics (2026)
Peer-reviewed article indexed in PubMed, published in The Journal of pharmacology and experimental therapeutics (2026).
- Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity — ACS chemical biology (2023)
Peer-reviewed article indexed in PubMed, published in ACS chemical biology (2023).
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.